Photodynamic therapy with verteporfin (Visudyne) is safe and effective in the treatment of subfoveal choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD). The third report of the Treatment of AMD With Photodynamic Therapy (TAP) Study Group, published in the November issue of the Archives of Ophthalmology, supports the benefits of this therapy.
“Verteporfin therapy can safely reduce the risk of moderate and severe vision loss in patients with subfoveal lesions that are predominantly classic CNV secondary to AMD,” write Neil M. Bressler, MD, from Johns Hopkins University in Baltimore, Maryland, and colleagues from the TAP Study Group. “While this benefit seemed to be even greater in the absence of occult CNV, the effect may be related to the smaller lesions and worse visual acuity associated with predominantly classic lesions without occult CNV and not solely to the lesion composition itself.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!